| 21/04/23 | 07:00:03 | 21 Apr 2023 | | Results for the year ended 31 December 2022 |
| 19/04/23 | 07:00:04 | 19 Apr 2023 | | ANGLE announces partnership with BioView |
| 17/04/23 | 07:00:07 | 17 Apr 2023 | | ANGLE Parsortix poster presented at AACR 2023 |
| 13/04/23 | 07:00:05 | 13 Apr 2023 | | Pharma Services Contract with Crescendo Biologics |
| 03/04/23 | 07:00:17 | 3 Apr 2023 | | Notice of Preliminary Results and Webcast |
| 10/03/23 | 07:00:07 | 10 Mar 2023 | | Issue of LTIP Options and Share Options |
| 09/03/23 | 15:03:05 | 9 Mar 2023 | | Holding(s) in Company |
| 09/02/23 | 14:44:50 | 9 Feb 2023 | | Director/PDMR shareholding |
| 19/01/23 | 07:00:08 | 19 Jan 2023 | | Appointment of Non-Executive Director |
| 11/01/23 | 17:20:01 | 11 Jan 2023 | | Holding(s) in Company |
| 10/01/23 | 18:20:01 | 10 Jan 2023 | | Holding(s) in Company |
| 06/01/23 | 11:05:18 | 6 Jan 2023 | | Second Price Monitoring Extn |
| 06/01/23 | 11:00:13 | 6 Jan 2023 | | Price Monitoring Extension |
| 05/01/23 | 09:05:21 | 5 Jan 2023 | | Second Price Monitoring Extn |
| 05/01/23 | 09:00:21 | 5 Jan 2023 | | Price Monitoring Extension |
| 05/01/23 | 07:01:01 | 5 Jan 2023 | | Appointment of Non-Executive Director |
| 05/01/23 | 07:00:06 | 5 Jan 2023 | | Business Update |
| 12/12/22 | 07:00:04 | 12 Dec 2022 | | Two Parsortix posters presented at SABCS |
| 02/12/22 | 17:30:01 | 2 Dec 2022 | | Issue of Equity |
| 02/11/22 | 07:00:09 | 2 Nov 2022 | | Multiple downstream analysis techniques for CTCs |
| 01/11/22 | 16:41:31 | 1 Nov 2022 | | Second Price Monitoring Extn |
| 01/11/22 | 16:35:57 | 1 Nov 2022 | | Price Monitoring Extension |
| 24/10/22 | 07:00:10 | 24 Oct 2022 | | Parsortix poster presented at ISLB meeting |
| 21/10/22 | 18:15:01 | 21 Oct 2022 | | Issue of Equity |
| 18/10/22 | 07:00:06 | 18 Oct 2022 | | Streamlining of operations to increase cash runway |
| 17/10/22 | 14:23:14 | 17 Oct 2022 | | TR-1: Notification of major holdings |
| 12/10/22 | 07:00:06 | 12 Oct 2022 | | First regional distribution agreement |
| 30/09/22 | 17:30:04 | 30 Sept 2022 | | Issue of Equity |
| 30/09/22 | 17:30:04 | 30 Sept 2022 | | Holding(s) in Company |
| 29/09/22 | 07:00:12 | 29 Sept 2022 | | Interim Results |
| 29/09/22 | 07:00:08 | 29 Sept 2022 | | Positive headline results from ovarian study |
| 28/09/22 | 07:00:12 | 28 Sept 2022 | | Study using Parsortix in head and neck cancer |
| 13/09/22 | 07:00:12 | 13 Sept 2022 | | New poster presented at ASCP Meeting |
| 12/09/22 | 07:30:47 | 12 Sept 2022 | | Novel assay predicts malignancy in pelvic mass |
| 01/09/22 | 07:00:09 | 1 Sept 2022 | | Notice of Interim Results and Webcast |
| 28/07/22 | 07:00:18 | 28 Jul 2022 | | Novel insight into metastasis in NSCLC patients |
| 20/07/22 | 14:33:25 | 20 Jul 2022 | | Holding(s) in Company |
| 20/07/22 | 07:00:09 | 20 Jul 2022 | | NEW STUDY OF PARSORTIX SYSTEM IN NSCLC |
| 19/07/22 | 10:00:03 | 19 Jul 2022 | | Director/PDMR Shareholding |
| 15/07/22 | 07:00:05 | 15 Jul 2022 | | Results of Capital Raise |
| 14/07/22 | 17:24:48 | 14 Jul 2022 | | Retail Offer via PrimaryBid |
| 14/07/22 | 17:23:27 | 14 Jul 2022 | | Proposed Placing and Retail Offer |
| 08/07/22 | 17:30:01 | 8 Jul 2022 | | Issue of Equity |
| 29/06/22 | 16:35:40 | 29 Jun 2022 | | Result of 2022 Annual General Meeting |
| 27/06/22 | 07:00:08 | 27 Jun 2022 | | Spread of breast cancer accelerates during sleep |
| 23/06/22 | 18:24:58 | 23 Jun 2022 | | Issue of Equity |
| 22/06/22 | 07:00:06 | 22 Jun 2022 | | Secured contract from pharma services customer |
| 16/06/22 | 07:00:09 | 16 Jun 2022 | | Predicting immunotherapy response in SCLC |
| 14/06/22 | 07:00:07 | 14 Jun 2022 | | Potential role of invasive cellular protrusions |
| 30/05/22 | 07:00:07 | 30 May 2022 | | Partnership with major United States urology group |
